Neuphoria Therapeutics (NASDAQ:NEUP) Rating Lowered to Sell at Wall Street Zen

Neuphoria Therapeutics (NASDAQ:NEUP) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

A number of other equities research analysts have also recently commented on NEUP. Weiss Ratings cut shares of Neuphoria Therapeutics from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, October 8th. Maxim Group increased their price objective on shares of Neuphoria Therapeutics from $18.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, September 11th. Finally, HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of Neuphoria Therapeutics in a research report on Tuesday, August 26th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $28.00.

Neuphoria Therapeutics Stock Performance

Shares of Neuphoria Therapeutics stock opened at $4.46 on Friday. The stock has a market cap of $23.99 million, a P/E ratio of -0.91 and a beta of 0.51. The stock’s fifty day moving average is $9.67 and its 200 day moving average is $8.43. Neuphoria Therapeutics has a one year low of $2.77 and a one year high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last issued its quarterly earnings results on Friday, November 14th. The company reported ($4.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($3.86). Analysts predict that Neuphoria Therapeutics will post -1.56 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Lynx1 Capital Management Lp acquired 639,110 shares of the business’s stock in a transaction on Tuesday, October 21st. The stock was acquired at an average cost of $5.14 per share, with a total value of $3,285,025.40. Following the acquisition, the insider directly owned 875,328 shares in the company, valued at $4,499,185.92. This represents a 270.56% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Neuphoria Therapeutics

A hedge fund recently bought a new stake in Neuphoria Therapeutics stock. Persistent Asset Partners Ltd purchased a new stake in shares of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,908 shares of the company’s stock, valued at approximately $58,000. Persistent Asset Partners Ltd owned about 0.21% of Neuphoria Therapeutics at the end of the most recent quarter. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.